Business Irish

Thursday 18 January 2018

Royalty Pharma drops hostile bid for drug maker Elan

Elan chief executive Kelly Martin at the pharma company’s EGM which was held yesterday in the Davenport Hotel, Dublin.
Elan chief executive Kelly Martin at the pharma company’s EGM which was held yesterday in the Davenport Hotel, Dublin.

Royalty ROYPH.UL on Tuesday withdrew its appeal against a ruling by Ireland's regulator on takeovers, meaning the offer automatically lapses and bringing an end to a bitter, four-month battle that involved court hearings, injunctions and a war of words between the two sides.

The end of that saga heralds a new takeover battle for Elan, which has invited bids and has interest from "more than one interested party," according to a source familiar with the situation.

Under Irish Takeover Panel rules, Royalty is not permitted to submit another hostile bid for Elan for 12 months once its current offer lapses. Elan has said Royalty can take part in the sale process. Royalty did not say if it intended to do so and a spokesman for the company had no further comment.

The New York-based investment firm had made its offer contingent on Elan shareholders rejecting all resolutions put to a vote at a meeting on Monday, but the owners narrowly backed one of the proposals, for a share buyback.

Royalty had said its bid should be contingent on only two of the resolutions relating to acquisitions - both of which were rejected - but the Irish Takeover Panel had said it could not modify the terms at that stage of the takeover contest.

ORIGINAL PLAN

Royalty subsequently appealed against this ruling, a move which it has now dropped.

"Royalty Pharma announced today that it had withdrawn its request for a judicial review of the Irish Takeover Panel's decision requiring it to lapse its offer for Elan Corporation," it said in a statement.

Elan, which rejected a third increased bid last week, has fended off Royalty, but shareholders have wrecked its original plan to spend the proceeds of a major drug sale on a string of acquisitions.

The Dublin-based firm set out on a spending spree last month after selling its 50pc interest in multiple sclerosis drug Tysabri to U.S. partner Biogen Idec (BIIB.O) for $3.25bn plus royalty rights.

But its owners overwhelmingly rejected a proposed $1bn royalties deal with U.S. company Theravance Inc (THRX.O), the purchase of private drug firm AOP Orphan and a drug spin-off aimed at cutting operating costs.

The Theravance deal, which would have given Elan 21pc of the royalties the U.S. firm is due to receive from GlaxoSmithKline (GSK) (GSK.L) for its respiratory drugs, was rejected by 72pc of shareholders.

Its agreed purchase of Austrian rare drug specialist AOP Orphan for €263.5m was voted down by a similarly wide margin. By contrast, just 50.1pc of shareholders supported the buyback.

Even before those votes, Elan kicked off its sale process on Friday, having said days earlier that it had received expressions of interest from other parties.

Royalty's bid had offered $13 in cash per share as well as a "contingent value right" that could add a further $2.50 per share if blockbuster drug Tysabri hit certain sales milestones.

Elan shares were slightly lower in early trade.

 

Reuters

Promoted Links

Business Newsletter

Read the leading stories from the world of Business.

Promoted Links

Also in Business